SCHEMBL5318170

SCHEMBL5318170

O=C(/C=C/c1ccccc1O)OCc1ccc(F)c(F)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.45
JUN P05412 1/20 0.45
NFE2L2 Q16236 1/20 0.45
CA4 P22748 2/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
ALOX5 P09917 2/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
BCHE P06276 1/20 0.41
GUSB P08236 1/20 0.41
AR P10275 2/20 0.41
MAPK1 P28482 2/20 0.41
MAOB P27338 1/20 0.41
AKR1B10 O60218 4/20 0.41
AKR1B1 P15121 4/20 0.41
CHRNA7 P36544 3/20 0.40
CA12 O43570 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11837578 0.77 MAPT (0.50) NFKB1JUNNFE2L2CA4CA1
SCHEMBL11837572 0.77 MAPT (0.50) NFKB1JUNNFE2L2CA4CA1
SCHEMBL13857111 0.77 MAOB (0.51) NFKB1JUNNFE2L2CA4CA1
SCHEMBL11837318 0.76 LMNA (0.67) NFKB1JUNNFE2L2CA4CA1
SCHEMBL11837322 0.76 LMNA (0.67) NFKB1JUNNFE2L2CA4CA1
SCHEMBL19901101 0.74 NFKB1 (0.59) NFKB1JUNNFE2L2CA4CA1
SCHEMBL2391128 0.73 MAPT (0.59) NFKB1JUNNFE2L2CA4CA1
SCHEMBL3132306 0.73 MAPT (0.59) NFKB1JUNNFE2L2CA4CA1
SCHEMBL78103 0.72 HCAR2 (0.53) CA4LMNAAKR1B10AKR1B1CA12
SCHEMBL2340792 0.72 HCAR2 (0.53) CA4LMNAAKR1B10AKR1B1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803809-A2 Modulation of peroxisome proliferator-activated receptors Abgenomics Corporation (TW) 2007-07-04 EP disclosed
US-20070037193-A1 Modulation of peroxisome proliferator-activated receptors ABGENOMICS CORPORATION (TW) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037193-A1 Modulation of peroxisome proliferator-activated receptors PPARG, PPARA, PPARD NFKB1 1541/4885JUN 2187/4885NFE2L2 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.